Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...

리더십 팀

이름	위치	테뉴어	보상	소유권
William Sibold	CEO, President & Director	less than a year	US$32.87m	데이터 없음
Rebecca Taub	Founder	12.8yrs	US$6.93m	5.11% $ 311.5m
Carole Huntsman	Chief Commercial Officer	less than a year	US$3.14m	데이터 없음
Mardi Dier	CFO & Senior VP	less than a year	데이터 없음	데이터 없음
Ronald Filippo	Chief Information Officer	less than a year	데이터 없음	데이터 없음
Tina Ventura	Chief Investor Relations Officer	less than a year	데이터 없음	데이터 없음
Justin Drinkwine	VP, Senior Associate General Counsel & Assistant Secretary	no data	데이터 없음	데이터 없음
Shannon Kelley	Chief Compliance Officer	no data	데이터 없음	데이터 없음
Clint Wallace	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Edward Chiang	Senior Vice President of Clinical & Technical Operations	no data	데이터 없음	데이터 없음
Thomas Hare	Senior Vice President of Clinical Management	no data	데이터 없음	데이터 없음
Robert Waltermire	Chief Pharmaceutical Development Officer	2.9yrs	데이터 없음	0.026% $ 1.6m

0.7yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: MDGL 의 관리팀은 경험 (평균 재직 기간 0.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
William Sibold	CEO, President & Director	less than a year	US$32.87m	데이터 없음
Rebecca Taub	Founder	8yrs	US$6.93m	5.11% $ 311.5m
Frederick Craves	Independent Lead Director	8yrs	US$65.00k	1.81% $ 110.2m
Kenneth Bate	Independent Director	8yrs	US$77.50k	0.0056% $ 342.4k
Julian Baker	Independent Chairman of the Board	1.1yrs	US$33.75k	0.011% $ 684.8k
Paul Friedman	Director	8yrs	US$9.80m	4.45% $ 271.2m
Richard Levy	Independent Director	7.9yrs	US$62.50k	0.048% $ 2.9m
James Daly	Independent Director	5.1yrs	US$57.50k	0.0056% $ 342.4k
Raymond Cheong	Independent Director	1.1yrs	US$27.50k	0.011% $ 684.8k

7.9yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: MDGL 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

Madrigal Pharmaceuticals 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Independent Lead Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Recent updates

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Madrigal: Powerful Catalyst Approaching

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

Madrigal Pharmaceuticals: Leading The NASH Innovation